In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Milestone Pharmaceuticals Inc (MIST – Research Report), with a price target of $32. The company’s shares closed last Monday at $16.80, close to its 52-week low of $15.
According to TipRanks.com, Baral is a 5-star analyst with an average return of 21.6% and a 46.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and NGM Biopharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Milestone Pharmaceuticals Inc with a $29.63 average price target.
The company has a one-year high of $27.95 and a one-year low of $15. Currently, Milestone Pharmaceuticals Inc has an average volume of 32.94K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Milestone Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. It designs and develops a rapid-onset nasal spray with Etripamil.